drugset / Trial / NCT06215859

Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy

NCT06215859

Phase 3 Completed 579 enrolled Viatris Specialty LLC Mylan Specialty, LP · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

MR-107A-02 is being studied to investigate its efficacy and safety for treatment of acute pain after herniorrhaphy.

Timeline

Start
2023-12-29
Primary completion
2025-01-31
Completion
2025-03-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MR-107A-02 Unknown 15 mg
Comparator Tramadol Other / unclassified 50 mg

Indications

No indication recorded.